The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Mar 2010
Multicenter StudyDenosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
Giant-cell tumour (GCT) of bone is a primary osteolytic bone tumour with low metastatic potential and is associated with substantial skeletal morbidity. GCT is rich in osteoclast-like giant cells and contains mononuclear (stromal) cells that express RANK ligand (RANKL), a key mediator of osteoclast activation. We investigated the potential therapeutic effect of denosumab, a fully human monoclonal antibody against RANKL, on tumour-cell survival and growth in patients with GCT. ⋯ Amgen, Inc.